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Introduction
Squamous cell carcinoma accounts for about 99% of
laryngeal malignancies. Non-epidermoid malignancies
of the larynx include sarcoma, lymphoma, and salivary
gland carcinoma. Salivary gland carcinomas of the 
larynx are rare tumors, which account for <1% of laryn-
geal malignancy.1 Few major series report on a detailed
MEDLINE search. The purpose of this study is to
review our experiences in diagnosis and therapy of
patients with salivary gland carcinoma in Taipei
Veterans General Hospital and to compare our treat-
ment results with those of other major existing series.
Methods
From 1981 to 2000, 1,564 patients with laryngeal
malignancy treated in Taipei Veterans General Hospital
were found from the computer database of the Cancer
Treatment Center. Twelve patients from among them
were diagnosed with salivary gland carcinoma of the
larynx. One of the 12 patients was excluded from our
study due to distant metastasis at the time of diagno-
sis. The remaining 11 patients were included in this
study. Demographic data, clinical staging of tumors,
pathologic classifications, treatment modalities, fail-
ure patterns, and survival were obtained by reviewing
the medical records. Tumors were staged according
to the 2002 American Joint Committee on Cancer
(AJCC) staging system for laryngeal tumors. All the
pathologic slides were re-examined by a single pathol-
ogist for histologic study. Clinical and pathologic data
were entered into a computer database (Microsoft
Access 2000) and statistical analysis of data was per-
formed by using a commercially available computer
software package (JMP 4.0, SAS Institute Inc., Cary,
NC, USA). The follow-up interval was calculated in
months from the date of initial surgery or radiother-
apy (RT) to the date of the last follow-up or death,
and disease-free interval was calculated from the date
of initial surgery or RT to the date of the first recur-
rence. For disease-specific survival, patients who died
of causes unrelated to laryngeal cancer were censored.
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Overall survival rates and disease-specific survival rates
were calculated using the Kaplan–Meier product-limit
method.
Results
All the 11 patients were male, aged from 48 to 84 years
with a median of 65. The demographic data, subsites
of primary tumor, and TNM staging system are shown
in Table 1. Three patients were at an early stage,
Stage I and II. Others were at the advanced Stage III
or IV.
The treatment modalities included surgery, surgery
with postoperative RT or RT alone (Table 1). A total of
9 patients (82%) underwent surgery. Surgery alone was
performed in 5 patients and surgery combined with
postoperative RT was used in 4 patients. Seven patients
underwent total laryngectomy. Only 2 patients had
conservation surgery, including 1 supraglottic partial
laryngectomy and 1 vertical partial laryngectomy. Neck
dissections were performed in 4 patients (2 unilateral
and 2 bilateral). Two patients received RT alone as their
mainstay treatment. Therefore, laryngeal preservation
rate was 36% (4/11) under surgery or RT.
All the pathologic slides were re-examined by a sin-
gle pathologist. Four patients were classified as having
adenoid cystic carcinoma (Table 1). Three patients
were classified with mucoepidermoid carcinoma and
3 patients with adenocarcinoma (Table 1). For surgi-
cal margins, 2 were positive and the remaining were
negative. Perineural invasion was noted in 2 patients
and both of them were adenoid cystic carcinoma. For
cell differentiation, intermediate grade predominated.
Only 1 case was high grade and 2 cases were low grade.
The median follow-up period was 95 months (range,
18–181 months). One patient developed local recur-
rence and 1 developed distant metastasis to the lung.
No patient had second primary tumor during the 
follow-up period. The overall survival rate was 71% in 
5 years, and 57% in 10 years. Disease-specific survival
was 83% in 5 years, and 63% in 10 years.
Discussion
Salivary gland carcinomas of the larynx are rare and
account for <1% of laryngeal malignancies.1 It was
about 0.76% in our series. Tumors of minor salivary
gland origin arise from subepithelial glands. Spiro 
et al reviewed 492 cases of tumors of minor salivary
gland origin in the head and neck in Memorial Hospital
during a 25-year period, and the most common origin
of minor salivary gland tumor was the palate (36.8%).2
Adenoid cystic carcinoma was the leading pathologic
diagnosis (35.4%). Only 3% of salivary gland tumors
were in the larynx. In the database of our cancer center,
salivary gland carcinomas of the larynx accounted for
Table 1. Epidemiologic characteristics of patients, histology, details of treatment, and outcome
Case Age Sex Primary site Stage Histology Treatment
Type of Laryngeal
Outcome
surgery preservation
1 48 M Glottic T3N0M0 ACC S TL No DNED at 239 mo
2 60 M Glottic T3N0M0 ACC RT Yes DNED at 120 mo
3 65 M Subglottic T4N0M0 AdenoCa RT Yes ANED at 123 mo
4 63 M Glottic T3N2bM0 AdenoCa S TL + ND No ANED at 91 mo
5 69 M Supraglottic T2N0M0 ACC S SGL Yes ANED at 94 mo
6 74 M Glottic T4N0M0 AdenoCa S + RT TL + ND No DNED at 31 mo
7 61 M Glottic T1N0M0 Mucoepi S + RT VPL Yes Local recurrence at
8 mo; ANED at
48 mo
8 79 M Glottic + T2N0M0 Mucoepi S + RT TL No ANED at 9 mo
subglottic
9 73 M Supraglottic T3N2cM0 Mucoepi S TL + ND No ANED at 122 mo
10 58 M Glottic + T4N0M0 ACC S + RT + C/T TL + ND No Died of lung 
subglottic due to lung metastasis 
metastasis at 22 mo
11 84 M Glottic + T3N0M0 AdenosquaCa S TL No
subglottic
ACC = adenoid cystic carcinoma; AdenoCa = adenocarcinoma; Mucoepi = mucoepidermoid carcinoma; AdenosquaCa = adenosquamous carcinoma; S = surgery;
RT = radiotherapy; C/T = chemotherapy; TL = total laryngectomy; ND = neck dissection; SGL = supraglottic laryngectomy; VPL = vertical partial laryngectomy;
DNED = died with no evidence of disease; ANED = alive with no evidence of disease.
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1.4% (12/856) of all head and neck salivary gland
carcinomas.
We reviewed 5 major series of a similar topic in 
the literature3–7 and compared them with our data
(Table 2). There were many more male than female
patients in most series except 1 (UCLA series) where
males and females were equal in number. The fact
that all the cases in our series were male may partly be
due to the fact that veterans were the major patient
population in our hospital. Salivary gland carcinomas
of the larynx account for a similar percentage of all
laryngeal malignancies, ranging from 0.6 to 0.87% in
these major series. Most tumors had supraglottic or
subglottic involvement,3,8 possibly because the distri-
bution density of subepithelial glands is higher in the
supraglottic and subglottic areas than in the glottic
area. Tumors arising from subepithelial glands1,2,9
begin as submucosal lesions, and are difficult to detect
earlier. This explains why most patients were diag-
nosed late at the advanced stage in all series. Toomey3
reported 8 cases of adenocarcinoma of the larynx and
reviewed 29 reported cases in the literature.4 In these
37 cases, male gender and old age were predominant.
Ninety-five percent of them had supraglottic or sub-
glottic involvement. The most frequent site of distant
metastasis was the lung. In our series, 63% of patients
had supraglottic or subglottic involvement, and the
site of distant metastasis was also the lung.
The symptoms and signs of laryngeal salivary gland
carcinoma are related to location and size.9 Patients
will suffer from dysphagia if the tumor is located in
the supraglottic area. Hoarseness or even dyspnea is
indicative of glottic involvement. Stridor and airway
obstruction might imply a subglottic tumor. The defi-
nite diagnosis of laryngeal salivary gland carcinoma is
made by biopsy of the laryngeal tumor under laryn-
goscope and histopathologic examination of the 
specimen.
Surgery with or without postoperative RT6,7,10,11
is the widely accepted major treatment modality of
laryngeal salivary gland carcinomas. Ipsilateral neck
dissection should be performed in cases with cervical
adenopathy, adenocarcinoma, and high-grade muco-
epidermoid carcinoma. Elective neck dissection is not
recommended for those who present with adenoid
cystic carcinoma and low-grade mucoepidermoid car-
cinoma.6,7,10,11 Surgery remains the mainstay treat-
ment for salivary gland carcinoma of the larynx.
Although aggressive treatment is recommended, the
role of RT is unclear, but it may be valuable as an
adjuvant modality for adenoid cystic carcinoma with
perineural spread, high-grade tumors, or positive sur-
gical margin. Chemotherapy may be useful as an adju-
vant therapy of high-grade lesions, either in conjunction
with surgery to prevent distant metastases or with RT
as palliation for patients with distant metastases at ini-
tial presentation.10
The 5-year overall survival in our series was 71%,
and the 5-year disease-specific survival was 83%.
Although we did not find any statistically significant fac-
tors of better prognosis due to the small sample size,
high-grade tumor cell type, positive surgical margin, or
perineural invasion still tend to be indicative of poor
prognosis. When compared with the treatment results
of squamous cell carcinoma of the larynx in our institute
between 1981 and 1991,12 we found the 5-year survival
rate to be 67% in squamous cell carcinoma of the larynx
and 71% in this study. These survival rates are similar.
In conclusion, laryngeal salivary gland carcino-
mas are rare. They account for <1% of laryngeal
Table 2. Data from different centers
Institute *Patient no. (%) Subsites of tumor (%) TNM stage Treatment (%) Survival (5 yr)
Barne’s hospital, 8/NA SG (37), SubG (13), I + II: 1 S (75), RT (25) 3 ANED/8
1967 TG (50) III + IV: 7
Memorial hospital, 17/2,500 (0.68) NA NA S (82), RT (18) 2 ANED/17
1968 2 AWD/17
Mayo Clinic, 1974 27/3,100 (0.87) SG (19), G (7), NA S (67), RT (33) Average survival
SubG (37), HY (4) 69 mo
MD Anderson, 18/2,967 (0.6) SG (78), SubG (22) I + II: 6 S (61), RT (11), DSS: 42.8%
1985 III + IV: 12 S + RT (28)
UCLA, 1999 12/1,547 (0.78) SG (42), G (33), I + II: 2 S (30), RT (0), OS: 45.2%
SubG (25) III + IV: 10 S + RT (70)
VGH, 2003 12/1,564 (0.76) SG (27), G (37), I + II: 2 S (55), RT (18), OS: 71%
SubG (9), TG (27) III + IV: 9 S + RT (27) DSS: 83%
*Number of patients with salivary gland carcinoma of the larynx over number of patients with laryngeal malignancy. SG = supraglottis; SubG = subglottis;
TG = transglottis; G = glottis; HY = hypopharynx; S = surgery; RT = radiotherapy; ANED = alive with no evidence of disease; AWD = alive with disease; DSS =
disease-specific survival; OS = overall survival; NA = not available.
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malignancies, and only 1–3% of head and neck salivary
gland carcinomas. They usually originate in the supra-
glottic or subglottic area with a predominance of male
gender and old age. Most patients were diagnosed late
at an advanced stage. Surgery alone or in combination
with postoperative RT is the main treatment modality.
The overall 5-year survival rate of laryngeal salivary
gland carcinoma is similar to that of laryngeal squa-
mous cell carcinoma in our institution.
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